Increase in the Company’s research potential through investment in laboratory infrastructure (Q111330): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Removed claim: summary (P836): The project will implement innovative technological solutions (process innovation) to increase the research potential of the ZF AMARA. The expected development of the research facilities of the ZF AMARA is mainly due to the technological regime of the current pharmaceutical industry, which is the applicant, an implemented action strategy focusing on continuous improvement of processes and existing legislation. The purchase of specialist resear...)
(‎Created claim: summary (P836): The subject of the project will be the implementation of innovative technological solutions (processing innovation) which will allow to increase the research potential of ZF AMARA. The assumed development of research facilities in ZF AMARA stems primarily from the technological regime in force in the pharmaceutical industry, in which the Applicant operates, implemented an action strategy focused on continuous process improvement and the applicab...)
Property / summary
 
The subject of the project will be the implementation of innovative technological solutions (processing innovation) which will allow to increase the research potential of ZF AMARA. The assumed development of research facilities in ZF AMARA stems primarily from the technological regime in force in the pharmaceutical industry, in which the Applicant operates, implemented an action strategy focused on continuous process improvement and the applicable legal provisions. The purchase of specialised research equipment will allow the applicants to extend the scope of research work according to the most current European Pharmacopoeia guidelines, increase the safety of the processes carried out (accurate, thorough product testing, e.g. solvent residues, determination of all known impurities and evaluation of their content in the product) and will allow a detailed assessment of the quality of the product. The main directions of the planned research work are: — Exemption analyses of medicinal products, pharmaceutical raw materials for recipes and medical devices. — Research on the stability of both medicinal products and cosmetics and testing of compatibility of cosmetics. — Continuous improvement of the technology of manufacturing pharmaceutical raw materials for pharmacy recipes and medicinal products. — Continuous improvement of existing products. — Development and implementation of new medicinal products – in response to the needs, expectations and requirements of customers. Experience in the implementation of research and investment projects, cooperation with an experienced research unit and long-standing knowledge of the industry ensure that the project will be implemented according to the assumptions. In conclusion, the medicinal products offered by ZF AMARA will be manufactured in a modern plant that meets strict GMP standards, ISO using new generation control and research devices, which will increase the competitiveness and innovation of the company and significantly increase the company’s scientific and technological potential. (English)
Property / summary: The subject of the project will be the implementation of innovative technological solutions (processing innovation) which will allow to increase the research potential of ZF AMARA. The assumed development of research facilities in ZF AMARA stems primarily from the technological regime in force in the pharmaceutical industry, in which the Applicant operates, implemented an action strategy focused on continuous process improvement and the applicable legal provisions. The purchase of specialised research equipment will allow the applicants to extend the scope of research work according to the most current European Pharmacopoeia guidelines, increase the safety of the processes carried out (accurate, thorough product testing, e.g. solvent residues, determination of all known impurities and evaluation of their content in the product) and will allow a detailed assessment of the quality of the product. The main directions of the planned research work are: — Exemption analyses of medicinal products, pharmaceutical raw materials for recipes and medical devices. — Research on the stability of both medicinal products and cosmetics and testing of compatibility of cosmetics. — Continuous improvement of the technology of manufacturing pharmaceutical raw materials for pharmacy recipes and medicinal products. — Continuous improvement of existing products. — Development and implementation of new medicinal products – in response to the needs, expectations and requirements of customers. Experience in the implementation of research and investment projects, cooperation with an experienced research unit and long-standing knowledge of the industry ensure that the project will be implemented according to the assumptions. In conclusion, the medicinal products offered by ZF AMARA will be manufactured in a modern plant that meets strict GMP standards, ISO using new generation control and research devices, which will increase the competitiveness and innovation of the company and significantly increase the company’s scientific and technological potential. (English) / rank
 
Normal rank
Property / summary: The subject of the project will be the implementation of innovative technological solutions (processing innovation) which will allow to increase the research potential of ZF AMARA. The assumed development of research facilities in ZF AMARA stems primarily from the technological regime in force in the pharmaceutical industry, in which the Applicant operates, implemented an action strategy focused on continuous process improvement and the applicable legal provisions. The purchase of specialised research equipment will allow the applicants to extend the scope of research work according to the most current European Pharmacopoeia guidelines, increase the safety of the processes carried out (accurate, thorough product testing, e.g. solvent residues, determination of all known impurities and evaluation of their content in the product) and will allow a detailed assessment of the quality of the product. The main directions of the planned research work are: — Exemption analyses of medicinal products, pharmaceutical raw materials for recipes and medical devices. — Research on the stability of both medicinal products and cosmetics and testing of compatibility of cosmetics. — Continuous improvement of the technology of manufacturing pharmaceutical raw materials for pharmacy recipes and medicinal products. — Continuous improvement of existing products. — Development and implementation of new medicinal products – in response to the needs, expectations and requirements of customers. Experience in the implementation of research and investment projects, cooperation with an experienced research unit and long-standing knowledge of the industry ensure that the project will be implemented according to the assumptions. In conclusion, the medicinal products offered by ZF AMARA will be manufactured in a modern plant that meets strict GMP standards, ISO using new generation control and research devices, which will increase the competitiveness and innovation of the company and significantly increase the company’s scientific and technological potential. (English) / qualifier
 
point in time: 20 October 2020
Timestamp+2020-10-20T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0

Revision as of 11:25, 20 October 2020

Project in Poland financed by DG Regio
Language Label Description Also known as
English
Increase in the Company’s research potential through investment in laboratory infrastructure
Project in Poland financed by DG Regio

    Statements

    0 references
    226,800.0 zloty
    0 references
    54,432.0 Euro
    13 January 2020
    0 references
    504,000.0 zloty
    0 references
    120,960.0 Euro
    13 January 2020
    0 references
    45.0 percent
    0 references
    1 October 2016
    0 references
    31 December 2017
    0 references
    ZAKŁAD FARMACEUTYCZNY "AMARA" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOSCIĄ
    0 references
    0 references
    Przedmiotem projektu będzie wdrożenie innowacyjnych rozwiązań technologicznych (innowacja procesowa), które umożliwią zwiększenie potencjału badawczego ZF AMARA. Zakładany rozwój zaplecza badawczego w ZF AMARA wynika przede wszystkim z reżimu technologicznego obowiązującego branżę farmaceutyczną, w której działa Wnioskodawca, wdrożonej strategii działania skoncentrowanej na ciągłym doskonaleniu procesów oraz obowiązujących przepisów prawa. Zakup specjalistycznych urządzeń badawczych pozwoli Wnioskodawcy rozszerzyć zakres prowadzonych prac badawczych według najbardziej aktualnych wytycznych Farmakopei Europejskiej, zwiększy bezpieczeństwo prowadzonych procesów (dokładne, wnikliwe przebadanie produktu np. pozostałości rozpuszczalników, oznaczanie wszystkich znanych zanieczyszczeń i ocena ich zawartości w produkcie) i pozwoli na szczegółową ocenę jakości produktu. Główne kierunki planowanych prac badawczych to: - Analizy zwolnieniowe produktów leczniczych, surowców farmaceutycznych do receptury oraz wyrobów medycznych. - Badania stabilności zarówno produktów leczniczych jak i kosmetyków oraz badania kompatybilności kosmetyków. - Stałe doskonalenie technologii wytwarzania surowców farmaceutycznych do receptury aptecznej oraz produktów leczniczych. - Nieustanne doskonalenie wyrobów istniejących. - Opracowywanie i wdrażanie nowych produktów leczniczych – w odpowiedzi na potrzeby, oczekiwania i wymagania Klientów. Doświadczenie w realizacji projektów badawczo-inwestycyjnych, współpraca z doświadczoną jednostką badawczą oraz wieloletnia znajomość branży gwarantują, że projekt zostanie zrealizowany zgodnie z założeniami. Reasumując, produkty lecznicze oferowane przez ZF AMARA będą wytwarzane w nowoczesnym zakładzie spełniającym surowe normy GMP, ISO przy wykorzystaniu urządzeń kontrolno-badawczych nowej generacji, co przełoży się na wzrost konkurencyjność i innowacyjność przedsiębiorstwa oraz wydatnie zwiększy potencjał naukowo-technologiczny Spółki. (Polish)
    0 references
    The subject of the project will be the implementation of innovative technological solutions (processing innovation) which will allow to increase the research potential of ZF AMARA. The assumed development of research facilities in ZF AMARA stems primarily from the technological regime in force in the pharmaceutical industry, in which the Applicant operates, implemented an action strategy focused on continuous process improvement and the applicable legal provisions. The purchase of specialised research equipment will allow the applicants to extend the scope of research work according to the most current European Pharmacopoeia guidelines, increase the safety of the processes carried out (accurate, thorough product testing, e.g. solvent residues, determination of all known impurities and evaluation of their content in the product) and will allow a detailed assessment of the quality of the product. The main directions of the planned research work are: — Exemption analyses of medicinal products, pharmaceutical raw materials for recipes and medical devices. — Research on the stability of both medicinal products and cosmetics and testing of compatibility of cosmetics. — Continuous improvement of the technology of manufacturing pharmaceutical raw materials for pharmacy recipes and medicinal products. — Continuous improvement of existing products. — Development and implementation of new medicinal products – in response to the needs, expectations and requirements of customers. Experience in the implementation of research and investment projects, cooperation with an experienced research unit and long-standing knowledge of the industry ensure that the project will be implemented according to the assumptions. In conclusion, the medicinal products offered by ZF AMARA will be manufactured in a modern plant that meets strict GMP standards, ISO using new generation control and research devices, which will increase the competitiveness and innovation of the company and significantly increase the company’s scientific and technological potential. (English)
    20 October 2020
    0 references

    Identifiers

    RPMP.01.02.02-12-0530/16
    0 references